within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX02_Sorafenib;

model Sorafenib
  extends Pharmacolibrary.Drugs.ATC.L.L01EX02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Sorafenib is a multikinase inhibitor approved for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and differentiated thyroid carcinoma. It acts by inhibiting tumor cell proliferation and angiogenesis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients (solid tumors), both male and female, after multiple oral doses.</p><h4>References</h4><ol><li><p>Jain, L, et al., &amp; Figg, WD (2011). Population pharmacokinetic analysis of sorafenib in patients with solid tumours. <i>British journal of clinical pharmacology</i> 72(2) 294–305. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2011.03963.x\">10.1111/j.1365-2125.2011.03963.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21392074/\">https://pubmed.ncbi.nlm.nih.gov/21392074</a></p></li><li><p>Chen, Y, et al., &amp; Pithavala, YK (2015). Axitinib plasma pharmacokinetics and ethnic differences. <i>Investigational new drugs</i> 33(2) 521–532. DOI:<a href=\"https://doi.org/10.1007/s10637-015-0214-x\">10.1007/s10637-015-0214-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25663295/\">https://pubmed.ncbi.nlm.nih.gov/25663295</a></p></li><li><p>Huh, KY, et al., &amp; Chung, JY (2021). Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib. <i>Pharmaceutics</i> 13(5) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics13050629\">10.3390/pharmaceutics13050629</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33925058/\">https://pubmed.ncbi.nlm.nih.gov/33925058</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Sorafenib;
